Vascular endothelial growth factor expression in serous ovarian carcinoma:: relationship with topoisomerase IIα and prognosis

被引:26
作者
Brustmann, H [1 ]
机构
[1] Thermenklinikum, Dept Pathol, A-2340 Moedling Vienna, Austria
关键词
vascular endothelial growth factor (VEGF); serous ovarian carcinoma; topoisomerase II alpha; prognosis; outcome; grade; stage;
D O I
10.1016/j.ygyno.2004.07.040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. This study investigated the expression of vascular endothelial growth factor (VEGF) and topoisomerase IIalpha (TPIIalpha) in a cohort of serous ovarian carcinomas by immunohistochemistry with regard to outcome and clinicopathologic variables. Methods. Formalin-fixed, paraffin-embedded archival tissue sections of 10 benign serous cystadenomas and 41 serous ovarian carcinomas were immunostained with antibodies to VEGF and TPIIalpha. Immunostaining for VEGF was scored with regard to quantity and intensity of positively stained cells as weak, focal strong, and diffuse strong. TPIIalpha labeling indices (LI) were quantitated as the percentage of positively stained nuclei in 1000 tumor cells. Results. VEGF expression was weak or negative in serous cystadenomas. In contrast, focal or diffuse strong immunostaining was observed in 21 cases (51%) of serous carcinomas. VEGF immunoreactivity was positively related with TPIIalpha LI (P=0.0055), adverse outcome (P=0.0052), high International Federation of Gynecology and Obstetrics (FIGO) stage (P=0.0158), and high tumor grade (P=0.0303). TPIIalpha LI increased with FIGO stage (P=0.0076) as well as tumor grade (P=0.0034) and indicated poor prognosis (P=0.0182). Conclusions. VEGF immunoreactivity is related with TPIIalpha LI and prognostically relevant. Expression of VEGF protein and TPIIalpha may serve as markers of aggressive tumor behavior in serous adenocarcinomas. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:16 / 22
页数:7
相关论文
共 31 条
[1]  
ALIOSMAN F, 1993, CANCER RES, V53, P5663
[2]  
[Anonymous], ATLAS TUMOR PATHOLOG
[3]   EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ITS RECEPTORS FLT AND KDR IN OVARIAN-CARCINOMA [J].
BOOCOCK, CA ;
CHARNOCKJONES, DS ;
SHARKEY, AM ;
MCLAREN, J ;
BARKER, PJ ;
WRIGHT, KA ;
TWENTYMAN, PR ;
SMITH, SK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (07) :506-516
[4]   Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study [J].
Brustmann, H .
GYNECOLOGIC ONCOLOGY, 2004, 92 (01) :268-276
[5]   Vascular endothelial growth factor expression in serous ovarian carcinoma:: Relationship with high mitotic activity and high FIGO stage [J].
Brustmann, H ;
Naudé, S .
GYNECOLOGIC ONCOLOGY, 2002, 84 (01) :47-52
[6]   Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival [J].
Chen, CA ;
Cheng, WF ;
Lee, CN ;
Chen, TM ;
Kung, CCS ;
Hsieh, FJ ;
Hsieh, CY .
GYNECOLOGIC ONCOLOGY, 1999, 74 (02) :235-240
[7]  
CIADIELLO F, 2003, CLIN CANCER RES, V9, P1546
[8]  
CORONAROTTI M, 1996, INT J CANCER, V67, P479
[9]   Topoisomerase IIα:: Prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum [J].
Costa, MJ ;
Hansen, CL ;
Holden, JA ;
Guinee, D .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2000, 19 (03) :248-257
[10]  
EDER JP, 1995, CANCER RES, V55, P6109